This debate arises because of anomalies and confounding factors in these four retrospective studies that cast doubt on the conclusions reached. Type 2 diabetes mellitus (T2DM) is itself associated with an increased incidence and risk of mortality from a range of cancers, 5, 6 and associated comorbidities and lifestyle factors, such as obesity and physical inactivity, are also associated with increased risk. 7 Furthermore, different diabetes treatments (which are often used concomitantly) can modify the risk of developing cancer (with metformin, for example, providing a protective effect 8, 9 ) and insulins and sulfonylureas potentially promoting tumor growth. 10, 11 This intricate web of interactions makes interpretation of epidemiologic studies difficult and, perhaps unsurprisingly given the controversial and far-reaching nature of the topic, the 2009 Diabetologia papers drew appropriate criticism over methodology. 12 In response, the European Medicines
Agency has now listed insulin analog and cancer safety as one of its priorities for drug safety research in 2011. 13 The insulin manufacturer Novo Nordisk (Copenhagen, 
THE INSULIN AND CANCER STORY -HOW IT ALL STARTED

Christopher Poole
How diabetes and its treatment affect cancer risk and outcome has been studied steadily over the last decade (driven primarily by oncologists).
The possibility that insulin analogs could affect cancer development differently to human insulin was first realized with the development of the X10 analog, as described below. However, four epidemiological papers published in In brief, the Hemkens study described a crude incidence of cancer that was higher with human insulin than with insulin analogs. 
Discussion Points Arising
The Finnish study, alone or in combination with similar data from other countries, may be of humans. 24 The importance of the IGF system for survival is demonstrated by the fact that it is highly conserved between species throughout evolution, particularly the gene encoding IGF-1. The IR exists as two isoforms, and cancer However, these residues can be enzymatically cleaved to produce two metabolites that do not have elevated IGF-1R affinity. 52 In summary, IGF-1R can be considered a proto-oncogene and the inhibition of its signaling is now being studied as a therapeutic target in oncology. Despite some continuing uncertainties, there are therefore theoretical reasons for avoiding the development of insulin analogs with increased IGF-1R affinity based on modifications that are not enzymatically cleaved.
It was noted that the evidence that insulin glargine is metabolized comes from an ex vivo study 52 This suggests that endocrine influences on cancer incidence can occur in shorter time-scales than popularly appreciated.
INSULIN MODIFICATION AND CONSEQUENCES FOR MITOGENICITY David Russell-Jones
The realization that artificial modifications of the insulin molecule could sometimes lead to unintended increases in mitogenic potential (ie, Whether IGF-1R affinity is of greater concern than increased IR residency time is unknown, but one in vitro study has suggested that the IGF-1R-mediated proliferative effect predominates in human fibroblasts. 65 Here respectively; not significant).
Discussion Points Arising
The greatest limitation of the glargine and 
PRINCIPLES FOR INSULIN ANALOG DEVELOPMENT
Bo Falck Hansen
The hypothesis that mitogenesis might at least in part be mediated via IGF-1R binding, and early reports 59 it is important to consider some principles of investigation that have been previously highlighted, 69 but which have been overlooked in several in vitro studies.
Firstly, it is important to realize that the relative potencies of different insulin analogs for given metabolic or mitogenic effects can only be determined from full dose-response curves. 69 An insulin-like molecule is likely to have at least some affinity for both IR and IGF-1R, so is potentially able to exert anything from zero to full response in cells carrying one or both receptor types, depending on its concentration (Figure 2 ). 69 Thus, comparisons of different another possibility. Such models will potentially enable clinically relevant data to be generated within practical timescales.
Discussion Points Arising
One appealing aspect of diabetic animals as test models is that they are less likely to be vulnerable to hypoglycemia, which has prevented the rodent toxicology study that showed an increase in cancer risk with X10 from being repeated for long-acting insulins. It is important that such models should be able to show a difference between no administration of a ligand, human insulin, and X10.
Concerning whether hyperglycemia would create a more representative environment in an animal model, it was noted that positron emission tomography scanning shows some cancer cells to be extremely efficient at loading glucose independently of insulin, with hypoxia being a powerful stimulus. This was not true of all cancer cells, however, with glucose uptake only detected for some when insulin is given.
MEETING CONCLUSION AND CONCLUDING DISCUSSIONS
Stephen Gough
Despite there being a growing knowledge base that should inform future discussions and research directions, current gaps in our 
